Company Profile
Precipio Diagnostics Stock Price, News & Analysis
- Ticker:
- PRPO
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
23.46 USD (-0.09%)
Close
Last updated: August 6, 2026
40.2M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, PRPO was little changed and closed at $23.46. No new same-company headline was identified in the current news window.
Company overview
Cancer Diagnostics Company
Precipio develops cancer diagnostic products and laboratory services. Its mission is to reduce diagnostic errors through more accurate testing products, optimized laboratory workflows, and clinical pathology services.
Laboratory Services and Product Development
The company designs, tests, validates, and uses diagnostic technologies in its own laboratory before commercializing them as proprietary products for laboratories worldwide. Revenue is generated from both pathology services and diagnostic product sales.
Integrated Business Model
Precipio combines services and products: the laboratory business provides a real-world clinical development environment, while the product business expands the reach of validated technologies. The release did not identify a specific future asset-level clinical or regulatory milestone.
Future catalysts
Precipio’s catalysts are diagnostic product adoption and any update that clarifies whether the company can keep building a niche lab-testing business. The market will care about recurring test usage more than a single headline.
Recent news
- 01
Precipio Announces Q2-2026 Shareholder Update Call
Source: Precipio Diagnostics
- 02
- 03
Precipio to Present at the Planet MicroCap Las Vegas
Source: Precipio Diagnostics
- 04
Precipio Announces Q1 2026 Financial Results
Source: Precipio Diagnostics
- 05
Management team’s 2025 market-based Options have vested
Source: Precipio Diagnostics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Precipio Diagnostics (PRPO)?
Precipio Diagnostics (PRPO) most recently closed at 23.46 USD, a -0.09% move versus the previous session.
What is the market cap of Precipio Diagnostics (PRPO)?
Precipio Diagnostics currently has a market capitalization of 40.2M USD on BioPharmSignal.
What does Precipio Diagnostics do?
Cancer Diagnostics Company Precipio develops cancer diagnostic products and laboratory services. Its mission is to reduce diagnostic errors through more accurate testing products, optimized laboratory workflows, and clinical pathology services. Laboratory Services and Product Development The company designs, tests, validates, and uses diagnostic...
On which exchange is PRPO stock listed?
Precipio Diagnostics (PRPO) is associated with NASDAQ, United States, MedTech.
What is Cancer?
Cancer Diagnostics Company Precipio develops cancer diagnostic products and laboratory services.
Which conditions is Precipio Diagnostics targeting with Cancer?
Precipio Diagnostics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Precipio Diagnostics describe recent progress with Cancer?
Precipio’s catalysts are diagnostic product adoption and any update that clarifies whether the company can keep building a niche lab-testing business. The market will care about recurring test usage more than a single headline.
What is Diagnostics?
Cancer Diagnostics Company Precipio develops cancer diagnostic products and laboratory services.